Short answer
LivaNova PLC (LIVN) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results cover the period ended June 30, 2026.
LivaNova PLC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results cover the period ended June 30, 2026
- Earnings press release furnished as Exhibit 99.1, containing the substantive financial details
- Business update conference call and webcast scheduled for August 5, 2026 at 1 p.m. London time
- Exhibit 99.1 not deemed filed under Exchange Act Section 18, limiting associated liability and incorporation by reference
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $390.6M, up 10.8% reported and 9.8% constant currency, with Cardiopulmonary and Neuromodulation both growing above 10%
- Adjusted diluted EPS $1.26 versus $1.05, while adjusted operating margin expanded to 23.2% from 21.9%
- Full-year constant-currency revenue guidance raised to 8%-9%, adjusted diluted EPS to $4.30-$4.40
- Adjusted free-cash-flow guidance reduced to $140M-$160M from $160M-$180M for Cardiopulmonary capacity, innovation and IT investments
- Thermo Fisher supply agreement targets oxygenator component shortages, supporting higher output and improved ability to meet demand
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LivaNova PLC 8-K filings
Get the next LIVN 8-K as it lands
Follow LIVN for push alerts, or ask the research agent what this filing means.